orantinib has been researched along with tegafur in 5 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (tegafur) | Trials (tegafur) | Recent Studies (post-2010) (tegafur) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 5,892 | 1,433 | 2,088 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Baba, H; Esaki, T; Fuse, N; Gotoh, M; Hara, T; Hosaka, H; Koizumi, W; Muro, K; Nakayama, N; Nishina, T; Sasaki, T; Sasaki, Y; Takagi, M; Takinishi, Y; Yamaguchi, K | 1 |
| Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS | 1 |
| Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H | 1 |
4 trial(s) available for orantinib and tegafur
| Article | Year |
|---|---|
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Fibroblast Growth Factors; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Tegafur; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Interleukin-6; Interleukin-8; L-Lactate Dehydrogenase; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Proto-Oncogene Proteins c-sis; Pyrroles; Tegafur; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Tegafur; Treatment Outcome | 2014 |
1 other study(ies) available for orantinib and tegafur
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |